We can now precisely edit the DNA genome of animals using a “molecular pencil” to erase, re-write, remove, or add genes. This allows researchers to target and select elite, desirable animal traits for animal welfare, disease resilience, and human health. Recombinetics is a global leader in food animal gene editing with many first-in-market advances.
The Food and Agricultural Organization of the United Nations expects global demand for meat and milk to double by 2050. To meet this demand, livestock producers must increase productivity without significantly increasing the amount of land, water and other agricultural inputs used for livestock production. Technological advances in gene editing will help meet this demand by rapidly accelerating genetic improvements with traits that impact productivity, animal health and animal welfare.
Today, it takes on average 15 years and $2 billion to bring a new drug to market. The U.S. pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. One reason for the high cost and long development cycle is that current animal models are poor predictors of patient response. We’ve cured cancer in mice over and over. It’s time for better models for preclinical research. It’s time for our pig models.
Numerous technological advances over the last decade make it possible to modify animal genomes accurately and efficiently. We use the gene-editing tools TALENs and CRISPR/Cas9 to help us replicate patient disease in large animal models for biomedical research, and to accelerate the improvement of agricultural genetics.
Our Intellectual Property far outpaces all our competitors. We have 170 patent filings and 13 patents on gene-editing-related discoveries, including many for the use of leading-edge gene-editing technologies, TALENs and CRISPR for livestock improvement. Our breakthrough discoveries lead to many industry “firsts” including the sale of the world’s first gene-edited pig to one of our many healthcare partners.